ストックスクリーナーアプリを入手
40.65
5.83%
2.24
アフターアワーズ：
40.10
-0.55
-1.35%
前日終値:
$38.41
開ける：
$38.11
24時間の取引高:
703.57K
Relative Volume:
0.48
時価総額：
$291.38M
収益：
-
当期純損益:
$-121.02M
株価収益率:
-3.6101
EPS:
-11.26
ネットキャッシュフロー:
$-114.09M
1週間 パフォーマンス:
+2.19%
1か月 パフォーマンス:
+115.31%
6か月 パフォーマンス:
+121.53%
1年 パフォーマンス:
-88.32%
1日の値動き範囲:
$38.06
$41.77
1週間の範囲:
$36.77
$44.30
52週間の値動き範囲:
$7.31
$363.20
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
名前
Tonix Pharmaceuticals Holding Corp
セクター
電話
212-980-9155
住所
26 MAIN STREET, SUITE 101, CHATHAM, NY
TNXP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
40.65 | 291.38M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-04-18 | 開始されました | Noble Capital Markets | Outperform |
| 2019-04-18 | アップグレード | ROTH Capital | Neutral → Buy |
| 2017-08-18 | アップグレード | ROTH Capital | Neutral → Buy |
| 2016-09-07 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 繰り返されました | Oppenheimer | Outperform |
| 2015-11-04 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-06-12 | 開始されました | Oppenheimer | Outperform |
| 2015-02-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-29 | 繰り返されました | ROTH Capital | Buy |
すべてを表示
Tonix Pharmaceuticals Holding Corp (TNXP) 最新ニュース
Tonix Pharmaceuticals to Showcase Rheumatologic Research at EULAR 2025 - citybuzz -
Tonix Pharmaceuticals Announces Poster Presentation at the Annua - GuruFocus
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Announces Poster Presentation at the - GlobeNewswire
Northern Trust Corp Acquires New Shares in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - Defense World
Tonix Pharmaceuticals (TNXP) Price Target Raised to $65 by Alliance Global Partners | TNXP Stock News - GuruFocus
Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell - Defense World
Tonix Pharmaceuticals: August PDUFA Date For Fibromyalgia Med A Risky Bet (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights - mx.advfn.com
How the (TNXP) price action is used to our Advantage - news.stocktradersdaily.com
Tonix Pharmaceuticals (TNXP) Stock Surges Over 10%: What's Fueling the Rally and What's Next? - Daily Chhattisgarh News
What's Going On With Tonix Pharmaceuticals Stock? - Benzinga
TNXP: Preparations Continue for Potential Commercial Launch of TNX-102 SL in Fibromyalgia… - Yahoo Finance
Tonix Pharmaceuticals CEO Highlights Strategic Vision at Healthcare Showcase - citybuzz -
Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase - GlobeNewswire
Tonix begins trial for stress reaction treatment By Investing.com - Investing.com South Africa
Tonix begins trial for stress reaction treatment - Investing.com Australia
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 O - GuruFocus
Tonix Pharmaceuticals (TNXP) Commences Phase 2 Trial for Stress Disorder Treatment | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Announces First Patient Dosed In Phase 2 Oasis Study Of TNX-102 SL For Reduction Of Acute Stress Reaction - marketscreener.com
Tonix Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
DoD Backs Revolutionary Acute Stress Treatment: First Patient Dosed in $3M Phase 2 Trial - Stock Titan
Tonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 Results - Benzinga
Stocks To Watch: Tonix Pharmaceuticals Sees RS Rating Jump To 89 - inkl
Tonix Pharmaceuticals Recruits Seasoned Industry Atty As GC - Law360
Tonix Pharma Stock Soars After Roping In Former Celgene Corp Executive Joseph Hand: Retail Gets More Positive - Investing.com India
Tonix Pharmaceuticals Names Joseph Hand as General Counsel and Executive Vice President of Operations - citybuzz -
Tonix Pharmaceuticals Appoints Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations - citybiz
Tonix Pharmaceuticals (TNXP) Appoints New General Counsel and EV - GuruFocus
Tonix Pharmaceuticals (TNXP) Appoints New General Counsel and EVP of Operations | TNXP Stock News - GuruFocus
Tonix Pharma Appoints New General Counsel and EVP - TipRanks
Tonix Pharmaceuticals Announces Appointment of Joseph Hand, - GlobeNewswire
Former Celgene $74B Deal Leader Joins Tonix as EVP Before Critical Fibromyalgia Drug Decision - Stock Titan
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Resul - GuruFocus
Tonix Pharmaceuticals Q1 2025 Earnings: EPS Loss of $2.84 Beats - GuruFocus
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Tonix Pharma earnings beat by $22.84, revenue fell short of estimates - Investing.com
Tonix Pharmaceuticals reports annual meeting results By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals reports annual meeting results - Investing.com Australia
Tonix showcases promising gastric cancer data at AACR Conference - Proactive financial news
(TNXP) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Tonix Pharma drops after Q4 revenue miss - MSN
Tonix Pharmaceuticals: Looking Past FDA Approval To Challenging Commercial Opportunity - Seeking Alpha
Tonix Pharmaceuticals Reveals Promising Preclinical Data for Cancer Immunotherapy TNX-1700 - citybuzz -
Tonix Pharma Unveils Promising Cancer Treatment Data - TipRanks
Tonix Pharmaceuticals Presented Preclinical Data on Gastric - GlobeNewswire
Tonix Pharmaceuticals (TNXP) Showcases Promising Cancer Research at AACR 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Canc - GuruFocus
Tonix Pharmaceuticals Holding Corp (TNXP) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):